We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00828932
Recruitment Status : Completed
First Posted : January 26, 2009
Last Update Posted : July 29, 2009
Information provided by:
Arena Pharmaceuticals

January 22, 2009
January 26, 2009
July 29, 2009
August 2008
December 2008   (Final data collection date for primary outcome measure)
The primary objective of this study is to evaluate the pharmacokinetic properties of lorcaserin in subjects with mild or moderate hepatic impairment compared to subjects with normal hepatic function.
Same as current
Complete list of historical versions of study NCT00828932 on ClinicalTrials.gov Archive Site
To evaluate the safety and tolerability of lorcaserin
Same as current
Not Provided
Not Provided
Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment
An Open Label, Single Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment
The purpose of this study is to evaluate and establish whether lorcaserin dose adjustment is required in patients with mild or moderate hepatic impairment.
Not Provided
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Hepatic Impairment
Drug: Lorcaserin
Experimental: Lorcaserin 10mg
Intervention: Drug: Lorcaserin
Christopher RJ, Morgan ME, Tang Y, Anderson C, Sanchez M, Shanahan W. Pharmacokinetics and Tolerability of Lorcaserin in Special Populations: Elderly Patients and Patients with Renal or Hepatic Impairment. Clin Ther. 2017 Apr;39(4):837-848.e7. doi: 10.1016/j.clinthera.2017.03.004. Epub 2017 Mar 30.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2008
December 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Males or females aged between 18 and 75 years (inclusive)
  2. Able to give signed informed consent
  3. Hepatic function will fall into one of the following categories:

    • One-third of patients will have normal hepatic function (defined as having all of the following parameters within the normal range of the clinical laboratory used for this trial: AST, ALT, alkaline phosphatase, total bilirubin)
    • One-third of patients will have mild impairment (Child-Pugh score 5-6)
    • One-third of patients will have moderate impairment (Child-Pugh score 7-9)
  4. All subjects will have a BMI of 27-45 kg/m2, inclusive.
  5. Eligible male and female patients must agree not to participate in a conception process
  6. Considered to be in stable health in the opinion of the Investigator.

Exclusion Criteria:

  1. Prior participation in any study of lorcaserin.
  2. Clinically significant new illness in the 1 month before screening
  3. Not suitable to participate in the study in the opinion of the Investigator including an existing physical or mental condition that prevents compliance with the protocol
  4. History of any of the following cardiovascular conditions:

    • Myocardial infarction (diagnosed by cardiac enzyme[s] and/or diagnostic ECG), CVA, TIA or RIND within 6 months of screening
    • Cardiac arrhythmia requiring initiation of new medical or surgical treatment within 6 months of screening (stable medical therapy for > 6 months, pacemakers and/or defibrillators implanted > 6 months prior to screening are acceptable)
    • Unstable angina
  5. Surgically implanted portacaval shunts are excluded with the following exception: transjugular intrahepatic portosystemic shunts (TIPS) will be allowed if placed no less than 3 months prior to dosing
  6. Malignancy within 2 years of the screening visit (except basal cell or squamous cell carcinoma with clean surgical margins)
  7. Initiation of a new prescription medication within 1 month prior to screening.
  8. Recent history (within 3 months prior to the screening visit) of alcohol or drug/solvent abuse or a positive screen for drugs of abuse at screening.
  9. Use of SSRI's, SNRI's, and other medications must meet the required washout periods.
  10. Participated in any clinical study with an investigational drug, biologic, or device within 1 month prior to dosing
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Christen Anderson, MD, PhD, Arena Pharmaceuticals, INc.
Arena Pharmaceuticals
Not Provided
Investigator: Christen Anderson, MD, PhD Arena Pharmaceuticals
Arena Pharmaceuticals
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP